Develops novel inhaled therapies targeting epithelial sodium channels (ENaC) to reduce mucus congestion in respiratory diseases like cystic fibrosis, asthma, and COPD. These treatments aim to decrease lung infections and improve respiratory function, addressing the underlying causes of chronic respiratory conditions affecting over 700 million people globally.
Funding
$33.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PPFounders
Product
Problem
Respiratory diseases like cystic fibrosis, asthma, and COPD cause mucus congestion in the lungs, leading to breathing difficulties, frequent lung infections, and a reduced quality of life for over 700 million people worldwide. Current treatments often fail to address the underlying mechanisms of mucus congestion, leaving a significant unmet need for disease-modifying therapies.
Solution
Enterprise Therapeutics is developing novel inhaled therapies that target epithelial sodium channels (ENaC) to reduce mucus congestion in respiratory diseases. Their lead asset, ETD001, is a long-acting ENaC blocker designed to increase fluid volume in the lungs, hydrate mucus, and improve mucociliary clearance. By addressing the root causes of mucus accumulation, these therapies aim to decrease the frequency of lung infections, improve respiratory function, and enhance the quality of life for patients with chronic respiratory conditions. ETD001 is currently undergoing Phase 2 clinical trials to assess its safety and efficacy in individuals with cystic fibrosis.
Target Audience
The primary target audience includes individuals suffering from respiratory diseases such as cystic fibrosis, asthma, and COPD, particularly those with mucus congestion and limited response to existing treatments.
Features
- ETD001: A novel, first-in-class inhaled ENaC blocker with a long-acting profile.
- Targets the epithelial sodium channel (ENaC) to increase airway hydration.
- Designed to improve mucociliary clearance and reduce mucus congestion in the lungs.
- CFTR mutation-agnostic approach, suitable for patients not benefiting from CFTR modulators.
- Demonstrated a strong safety profile in Phase 1 trials with healthy participants.
- Currently in Phase 2 clinical trials to assess safety and efficacy in cystic fibrosis patients.